Imatinib-ULS-lysozyme: A proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases
- 3 September 2011
- journal article
- research article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 157 (3), 461-468
- https://doi.org/10.1016/j.jconrel.2011.08.041
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Noncanonical TGF-β pathways, mTORC1 and Abl, in renal interstitial fibrogenesisAmerican Journal of Physiology-Renal Physiology, 2010
- Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase ConformationsCancer Research, 2009
- Angiogenesis in the kidney: a new therapeutic target?Current Opinion in Nephrology and Hypertension, 2009
- Inhibition of Renal Rho Kinase Attenuates Ischemia/Reperfusion-Induced InjuryJournal of the American Society of Nephrology, 2008
- Effects of the Protein Kinase Inhibitor, Imatinib Mesylate, on Epithelial/Mesenchymal Phenotypes: Implications for Treatment of Fibrotic DiseasesJournal of Pharmacology and Experimental Therapeutics, 2007
- AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLBritish Journal of Cancer, 2006
- Renal fibrosis: New insights into the pathogenesis and therapeuticsKidney International, 2006
- Role of atrophic changes in proximal tubular cells in the peritubular deposition of type IV collagen in a rat renal ablation modelNephrology Dialysis Transplantation, 2005
- Imatinib treatment: Specific issues related to safety, fertility, and pregnancySeminars in Hematology, 2003
- Megalin Knockout Mice as an Animal Model of Low Molecular Weight ProteinuriaThe American Journal of Pathology, 1999